Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars

Executive Summary

Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency, says Irish health minister Simon Harris. The minister has also outlined his department’s approach to high drug pricing and says he expects a national biosimilars policy by the end of the year.

You may also be interested in...



EMA Suspends Some Activities To Focus On Brexit Relocation

The EMA has given some details of its business continuity plan for Brexit preparedness, which includes diverting some resources from lower-priority tasks to focus on core activities.

Medicines For Ireland Lays Out Priorities For Boosting Access To Generics And Biosimilars

A new Irish generics medicines body has published a policy manifesto calling on the government to take action on pricing, competition, biosimilars and market access.

EU Postpones Decision On EMA’s New Home To November

The decision on where the European Medicines Agency should be located after the UK leaves the EU has been postponed to November. The European Council has published details of the bidding process countries must follow if they want to host the EMA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB002137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel